447 filings
Page 4 of 23
6-K
9dkin 7djezyj0yng0f
13 Mar 23
Current report (foreign)
9:00am
6-K
e4tfeu6cizi4yxh
21 Feb 23
Current report (foreign)
8:06am
6-K
sv204 0uo4zn0r
15 Feb 23
Current report (foreign)
4:30pm
6-K
g4pj3jo f9kqcia96h
15 Feb 23
Current report (foreign)
8:05am
6-K
qpssbdbiqwfd9
13 Feb 23
Current report (foreign)
8:05am
6-K
aaeh6xps yddhtk709
10 Nov 22
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
4:44pm
424B3
40bxh8wjop
9 Nov 22
Prospectus supplement
4:11pm
EFFECT
qox17c
9 Nov 22
Notice of effectiveness
12:15am
6-K
w5x8kr9i7l5b1b
8 Nov 22
Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer
4:34pm
CORRESP
5n2sare7
7 Nov 22
Correspondence with SEC
12:00am
F-1/A
yjatzaplxopv1xzkf
4 Nov 22
Registration statement (foreign) (amended)
5:00pm
6-K
5gwtd8hvc46d ubst
28 Oct 22
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
4:34pm
UPLOAD
mtrtmki17h0
19 Oct 22
Letter from SEC
12:00am
F-1
42eezbzqzbq
12 Oct 22
Registration statement (foreign)
4:31pm
6-K
142vht8 ca7
27 Sep 22
Current report (foreign)
4:30pm
D
2wbdwvcu
27 Sep 22
$12.84M in options / securities to be acquired, sold $12.84M, 21 investors
4:16pm
424B5
4bs6q3ho5va
14 Sep 22
Prospectus supplement for primary offering
12:19pm
6-K
xa44w1va1l9
14 Sep 22
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
12:02pm
6-K
bxqrrz2aj0 mb7z3
1 Aug 22
Current report (foreign)
5:00pm
6-K
kwih4klr
29 Jul 22
Current report (foreign)
5:00pm